Pacira Stock Story


USD 57.95  0.22  0.38%   

As many millenniums are getting more into healthcare space, we are going to break down Pacira Pharm and Canntrust Holdings as potential short-term trade. We are going to inspect some of the competitive aspects of both Pacira and Canntrust.
Published over three months ago
View all stories for Pacira Pharm | View All Stories

Will Pacira Pharm (NASDAQ:PCRX) investors shift to Canntrust (NASDAQ:CNTTQ)?

By analyzing existing basic indicators between Pacira Pharm and Canntrust, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Canntrust with a short position in Pacira Pharm. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pacira Pharm has an asset utilization ratio of 132.39 percent. This suggests that the company is making $1.32 for each dollar of assets. An increasing asset utilization means that Pacira Pharm is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Pacira or Exxon is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Pacira Pharm's Liquidity

Pacira Pharm financial leverage refers to using borrowed capital as a funding source to finance Pacira Pharm ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Pacira Pharm financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Pacira Pharm's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Pacira Pharm, but it might be worth checking our own buy vs. sell analysis

Correlation Between Pacira and Exxon Mobil Corp

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Pacira Pharm together with similar or unrelated positions with a negative correlation. For example, you can also add Exxon to your portfolio. If Exxon is not perfectly correlated to Pacira Pharm it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Pacira Pharm for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Please check pair correlation details between PCRX and XOM for more information.

Sale by Slonin Jonathan of 308 shares of Pacira Pharm

Legal trades by Pacira Pharm insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Pacira insider trading alert for sale of common stock by Slonin Jonathan, Chief Clinical Officer, on 5th of August 2022. This event was filed by Pacira Biosciences Inc with SEC on 2022-08-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Let me now analyze Pacira Pharm revenue. Based on the latest financial disclosure, Pacira Pharm reported 513.31 M of revenue. This is 93.27% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 94.56% higher than that of the entity. As for Canntrust Holdings we see revenue of 54.66 M, which is much higher than that of the Drug Manufacturers—Specialty & Generic

513.3 M
PCRX513.31 Million90.38
CNTTQ54.66 Million9.62

Pacira Pharm bad stories are not so bad

Current semi variance is at 4.26. Pacira Pharm currently demonstrates below-average downside deviation. It has Information Ratio of 0.16 and Jensen Alpha of 0.34. However, we advise investors to further question Pacira Pharm expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Pacira Pharm's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Pacira Pharm's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Pacira Pharm Implied Volatility

Pacira Pharm's implied volatility exposes the market's sentiment of Pacira Pharm stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Pacira Pharm's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Pacira Pharm stock will not fluctuate a lot when Pacira Pharm's options are near their expiration.

Our Final Take On Pacira Pharm

While other companies in the drug manufacturers—specialty & generic industry are either recovering or due for a correction, Pacira may not be as strong as the others in terms of longer-term growth potentials. While some investors may not share our view, we believe it may be a good time to increase your existing holdings in Pacira. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Pacira Pharm.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Pacira Pharm. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to